Prognostic relevance of HER2 expression and gene amplification in estrogen receptor-positive lymph-node negative breast cancer patients

被引：0
|
作者：
Peiro, G. [1 ]
Adrover, E. [1 ]
Aranda, F. [1 ]
Alenda, C. [1 ]
Peiro, F. [1 ]
Segui, J. [1 ]
机构：
[1] Univ Alacant, Gen Hosp, Dept Pathol, Alicante, Spain
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [1] Pathological Prognostic Factors in Estrogen Receptor Positive/Her2 Negative and Lymph Node Negative Breast Cancers
    Mendoza, Pia
    Sonmez, Ceyda
    Zhang, Chao
    Neely, Cameron
    Liu, Yuan
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2017, 97 : 59A - 59A
  • [2] Pathological Prognostic Factors in Estrogen Receptor Positive/Her2 Negative and Lymph Node Negative Breast Cancers
    Mendoza, Pia
    Sonmez, Ceyda
    Zhang, Chao
    Neely, Cameron
    Liu, Yuan
    Li, Xiaoxian
    MODERN PATHOLOGY, 2017, 30 : 59A - 59A
  • [3] Low Progesterone Receptor Expression Is Associated with Distant Metastasia in Estrogen Receptor Positive/HER2 Negative and Lymph Node Negative Breast Cancer
    Mendoza, Pia
    Sonmez, Ceyda
    Neely, Cameron
    Zhang, Chao
    Liu, Yuan
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2017, 97 : 59A - 59A
  • [4] Low Progesterone Receptor Expression Is Associated with Distant Metastasis in Estrogen Receptor Positive/HER2 Negative and Lymph Node Negative Breast Cancer
    Mendoza, Pia
    Sonmez, Ceyda
    Neely, Cameron
    Zhang, Chao
    Liu, Yuan
    Li, Xiaoxian
    MODERN PATHOLOGY, 2017, 30 : 59A - 59A
  • [5] Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer
    Rakha, Emad A.
    Agarwal, Devika
    Green, Andrew R.
    Ashankyty, Ibraheem
    Ellis, Ian O.
    Ball, Graham
    Alaskandarany, Mohammed A.
    HISTOPATHOLOGY, 2017, 70 (04) : 622 - 631
  • [6] Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
    Van Asten, Kathleen
    Slembrouck, Laurence
    Olbrecht, Siel
    Jongen, Lynn
    Brouckaert, Olivier
    Wildiers, Hans
    Floris, Giuseppe
    Van Limbergen, Erik
    Weltens, Caroline
    Smeets, Ann
    Paridaens, Robert
    Giobbie-Hurder, Anita
    Regan, Meredith M.
    Viale, Giuseppe
    Thurlimann, Beat
    Vergote, Ignace
    Christodoulou, Evangelia
    Van Calster, Ben
    Neven, Patrick
    ONCOLOGIST, 2019, 24 (02): : 165 - 171
  • [7] Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
    Fisher, B
    Dignam, J
    Wolmark, N
    DeCillis, A
    Emir, B
    Wickerham, DL
    Bryant, J
    Dimitrov, NV
    Abramson, N
    Atkins, JN
    Shibata, H
    Deschenes, L
    Margolese, RG
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (22): : 1673 - 1682
  • [8] Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
    Atkins, CD
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (06) : 468 - 468
  • [9] EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS
    Shen, Jun
    Wang, Lin-bo
    Teng, Rong-yue
    Shen, Jian-guo
    ACTA MEDICA MEDITERRANEA, 2022, 38 (03): : 1595 - 1600
  • [10] Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Paik, Soonmyung
    Tang, Gong
    Shak, Steven
    Kim, Chungyeul
    Baker, Joffre
    Kim, Wanseop
    Cronin, Maureen
    Baehner, Frederick L.
    Watson, Drew
    Bryant, John
    Costantino, Joseph P.
    Geyer, Charles E., Jr.
    Wickerham, D. Lawrence
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) : 3726 - 3734
12345